Channel passion into potential
Our clinical trials help us investigate our product candidates’ novel capabilities.
To learn more about our current clinical trials, including eligibility, locations, and the process for potentially participating in a study, visit clinicaltrials.gov in the U.S.,
clinicaltrialsregister.eu in the EU, or https://jrct.niph.go.jp in Japan.
Our Commitment to Clinical Trial Transparency
At Insmed, we are deeply committed to ensuring that our clinical research is conducted responsibly and transparently, in full compliance with applicable laws and regulations, while protecting patient data. We are proud to have dedicated and trained staff to ensure timely registration of clinical trials and communication of our research results, and we work closely with external experts and thought leaders to ensure our work reflects the latest clinical and scientific advances.
Our current clinical trial transparency practices include:
Data Privacy
As guardians of data about the patients who use our medicines, as well as their caregivers and the healthcare professionals who serve them, we are committed to handling personal data in accordance with global laws and regulations that govern data protection and privacy.
Clinical Trial Registration
Insmed registers company-sponsored Phase 1 to 4 clinical trials on public clinical registry sites as required by global laws and regulations.
To learn more about our current clinical trials, please visit the following websites:
- U.S.: www.clinicaltrials.gov
- Europe: www.clinicaltrialsregister.eu
- Japan: https://jrct.niph.go.jp
Clinical Trial Results
Insmed discloses company-sponsored Phase 1 to 4 clinical trial results on public registries in compliance with global results disclosure laws and regulations.
To find clinical trial results for our completed trials, please visit the following websites:
- U.S.: www.clinicaltrials.gov
- Europe: clinicaltrialsregister.eu
- Japan: https://jrct.niph.go.jp
Clinical Trial Lay Language Summary Results
In addition to posting results from our clinical trials, Insmed discloses lay language summary results on https://goodday.health to help ensure that our results are understandable to patients and other general audiences.
Our clinical trials
Amikacin Liposome Inhalation Suspension
Nontuberculous Mycobacterial (NTM) Lung Disease
A Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ENCORE)
Our ENCORE study of patients with NTM lung disease caused by Mycobacterium avium complex (MAC) is currently underway.
Brensocatib
Non-cystic Fibrosis Bronchiectasis (NCFBE)
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)
The Phase 3 ASPEN study of patients with NCFBE is currently underway.
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
If you have CRSsNP, you may be eligible for the Phase 2 BiRCh study.
See if you may qualify BiRCh
Hidradenitis Suppurativa (HS)
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
If you have HS, you may be eligible for the Phase 2 CEDAR study.
See if you may qualify CEDAR
Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Our Phase 2 study of patients with PH-ILD is currently underway.
Pulmonary Arterial Hypertension (PAH)
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Our Phase 2 study of patients with PAH is currently underway.
Gene Therapy
Duchenne Muscular Dystrophy (DMD)
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD) (ASCEND)
If your child has DMD, they may be eligible for the ASCEND study.
See if they may qualify ASCEND
Our clinical trials
NCFBE
The Phase 3 ASPEN study of patients with non-cystic fibrosis bronchiectasis (NCFBE) is currently underway.
NTM LUNG DISEASE CAUSED BY MAC
If you have nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC), you may be eligible for our clinical trial.
PULMONARY HYPERTENSION
If you have pulmonary hypertension associated with interstitial lung disease (PH-ILD) or pulmonary arterial hypertension (PAH), you may be eligible for an Insmed study.
To learn about study sites near you, email medicalinformation@Insmed.com, call 1-844-446-7633 (within the United States), or visit https://insmed.com/med-info/ for a list of phone numbers outside the United States.
CRSsNP
If you have chronic rhinosinusitis without nasal polyps (CRSsNP), you may be eligible for the Phase 2 BiRCh study.
Your Privacy Choices
